Analysts expect ENDRA Life Sciences Inc (NASDAQ:NDRA) to announce earnings of ($0.21) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for ENDRA Life Sciences’ earnings. ENDRA Life Sciences reported earnings per share of ($0.31) during the same quarter last year, which would suggest a positive year over year growth rate of 32.3%. The business is scheduled to issue its next earnings results on Thursday, August 13th.
On average, analysts expect that ENDRA Life Sciences will report full-year earnings of ($0.82) per share for the current fiscal year. For the next financial year, analysts anticipate that the company will report earnings of ($0.58) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for ENDRA Life Sciences.
ENDRA Life Sciences (NASDAQ:NDRA) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.29) EPS for the quarter, meeting analysts’ consensus estimates of ($0.29).
A hedge fund recently raised its stake in ENDRA Life Sciences stock. ICM Asset Management Inc. WA raised its position in shares of ENDRA Life Sciences Inc (NASDAQ:NDRA) by 32.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 876,639 shares of the company’s stock after acquiring an additional 212,755 shares during the period. ENDRA Life Sciences makes up approximately 0.6% of ICM Asset Management Inc. WA’s investment portfolio, making the stock its 21st largest position. ICM Asset Management Inc. WA owned about 6.37% of ENDRA Life Sciences worth $633,000 at the end of the most recent reporting period. 7.86% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ENDRA Life Sciences stock traded down $0.03 during trading on Friday, reaching $0.93. The stock had a trading volume of 901,000 shares, compared to its average volume of 230,386. The company has a market capitalization of $13.93 million, a price-to-earnings ratio of -0.41 and a beta of 1.80. The stock has a fifty day moving average price of $0.86 and a two-hundred day moving average price of $1.10. ENDRA Life Sciences has a 52 week low of $0.60 and a 52 week high of $2.25. The company has a current ratio of 2.43, a quick ratio of 2.32 and a debt-to-equity ratio of 0.13.
About ENDRA Life Sciences
ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
Further Reading: Why are analyst ratings important in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.